|
시장보고서
상품코드
2050497
테이-삭스병 시장 : 질환 유형별, 치료법별, 투여 경로별, 최종사용자별, 유통 채널별, 지역별Tay-Sachs Disease Market, By Disease Type, By Treatment Type, By Route of Administration, By End User, By Distribution Channel, By Geography |
||||||
테이-삭스병 시장은 2026년에 28억 1,000만 달러로 추정되고 있으며, 2033년까지 44억 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 6.6%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 28억 1,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 6.60% | 2033년 시장 규모 예측 : | 44억 달러 |
테이삭스병은 헥소사미니다제 A 효소 결핍으로 인해 신경세포 내에 GM2 강글리오사이드가 축적되는 희귀한 진행성 신경퇴행성 질환입니다. 이 상염색체 열성 유전병은 주로 영아에게 영향을 미치며, 심각한 신경학적 기능 저하를 일으켜 보통 생후 몇 년 이내에 사망에 이르게 합니다. 글로벌 테이삭스병 시장에는 치료 중재, 진단 툴, 효소 대체요법, 유전자 치료, 증상 관리 및 질병 진행을 억제하는 것을 목표로 하는 지지요법 솔루션이 포함됩니다.
이 질환은 주로 아슈케나지 유대인, 프랑스계 캐나다인, 케이준계 혈통을 가진 개인에게 발병하지만, 인식의 증가와 유전자 검사 기술의 향상으로 전 세계에서 시장 인지도가 확대되고 있습니다. 시장 상황에는 혁신적인 치료법을 개발하는 제약사, 보균자 검사 및 산전 검사를 제공하는 진단 검사 기관, 희귀 유전 질환을 전문으로 하는 의료 서비스 제공자 등이 포함됩니다. 현재 치료의 초점은 기질 감소 요법, 효소 보충 요법 및 근본적인 효소 결핍을 해결하기 위한 새로운 유전자 치료 접근법에 맞춰져 있습니다. 또한 이 시장에는 발작, 섭식장애, 호흡기 합병증 등의 증상 관리를 지원하는 완화치료 제품 및 서비스도 포함되어 있으며, 환자와 그 가족에 대한 포괄적인 치료의 필요성을 반영하고 있습니다.
시장 역학
세계의 테이삭스병 시장은 희귀 유전성 질환에 대한 인식 증가, 진단 능력 향상, 희귀질환 치료제 개발에 대한 투자 확대 등 몇 가지 강력한 요인에 의해 주도되고 있습니다. 희귀질환 치료제 지정, 시장 독점 기간 연장, 신속한 승인 절차 등의 규제적 인센티브는 제약사들이 희귀질환에 대한 연구개발에 투자하는 것을 장려하고 있습니다. 특히 고위험군에서의 유전상담 및 보인자 선별검사 프로그램의 보급 확대는 조기 진단과 시장 확대에 기여하고 있습니다. 또한 바이러스 벡터를 이용한 접근법이나 유전체 편집 기술을 포함한 유전자 치료 기술의 발전은 유망한 치료법으로 많은 연구 자금과 상업적 관심을 받고 있습니다.
그러나 이 시장은 환자 수가 극히 적다는 큰 제약에 직면해 있으며, 이는 제약사의 상업적 타당성 및 투자수익률을 제한하고 있습니다. 희귀질환 치료제의 높은 개발 비용과 복잡한 규제 요건 및 장기간에 걸친 임상시험 과정은 시장 진입에 큰 장벽으로 작용하고 있습니다. 특수 치료법의 제조상의 어려움, 특정 지역의 의료 인프라 부족, 조기 사망으로 이어지는 질병의 심각한 특성도 시장 성장을 더욱 제한하고 있습니다. 이러한 과제에도 불구하고 헬스케어 체계가 개선되고 있는 신흥 시장, 학술기관과 제약사 간 협력 강화, 환자 지원 활동 확대 등 기회가 존재합니다. 질병 모니터링을 위한 바이오마커 개발, 신생아 스크리닝 프로그램 확대, 잠재적인 병용요법 접근법은 향후 성장을 주도하고 환자 예후를 개선할 수 있는 추가적인 시장 기회를 의미합니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 매출기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계의 테이삭스병 시장의 주요 기업 개요을 작성했습니다. 구체적으로는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 세계 테이삭스병 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 금융 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 글로벌 테이삭스병 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 테이-삭스병 시장 : 질환 유형별, 2021-2033년
제5장 세계의 테이-삭스병 시장 : 치료 유형별, 2021-2033년
제6장 세계의 테이-삭스병 시장 : 투여 경로별, 2021-2033년
제7장 세계의 테이-삭스병 시장 : 최종사용자별, 2021-2033년
제8장 세계의 테이-삭스병 시장 : 유통 채널별, 2021-2033년
제9장 세계의 테이-삭스병 시장 : 지역별, 2021-2033년
제10장 경쟁 구도
제11장 애널리스트의 제안
제12장 참고 문헌 및 조사 방법
KSA 26.06.10Tay-Sachs Disease Market is estimated to be valued at USD 2.81 Bn in 2026 and is expected to reach USD 4.40 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.81 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.60% | 2033 Value Projection: | USD 4.40 Bn |
Tay-Sachs disease represents a rare, progressive neurodegenerative disorder caused by deficiency of the hexosaminidase A enzyme, resulting in the accumulation of GM2 ganglioside in nerve cells. This autosomal recessive genetic condition primarily affects infants and children, leading to severe neurological deterioration and typically proving fatal within the first few years of life. The global Tay-Sachs disease market encompasses therapeutic interventions, diagnostic tools, enzyme replacement therapies, gene therapies, and supportive care solutions designed to manage symptoms and potentially alter disease progression.
While the condition predominantly occurs in individuals of Ashkenazi Jewish, French-Canadian, and Cajun descent, increased awareness and improved genetic screening have expanded market recognition worldwide. The market landscape includes pharmaceutical companies developing innovative treatment approaches, diagnostic laboratories offering carrier screening and prenatal testing, and healthcare providers specializing in rare genetic disorders. Current therapeutic focus centers on substrate reduction therapy, enzyme replacement therapy, and emerging gene therapy approaches that aim to address the underlying enzymatic deficiency. The market also encompasses palliative care products and services that help manage symptoms such as seizures, feeding difficulties, and respiratory complications, reflecting the comprehensive care requirements for affected patients and their families.
Market Dynamics
The global Tay-Sachs disease market is driven by several compelling factors, including increased awareness of rare genetic disorders, improved diagnostic capabilities, and growing investment in orphan drug development. Regulatory incentives such as orphan drug designation, extended market exclusivity periods, and accelerated approval pathways encourage pharmaceutical companies to invest in research and development for this ultra-rare condition. The rising prevalence of genetic counseling and carrier screening programs, particularly in high-risk populations, contributes to earlier diagnosis and market expansion. Additionally, advancements in gene therapy technologies, including viral vector-based approaches and genome editing techniques, present promising therapeutic avenues that attract significant research funding and commercial interest.
However, the market faces substantial restraints, primarily the extremely small patient population, which limits commercial viability and return on investment for pharmaceutical companies. The high cost of drug development for rare diseases, coupled with complex regulatory requirements and lengthy clinical trial processes, creates significant barriers to market entry. Manufacturing challenges for specialized therapies, limited healthcare infrastructure in certain regions, and the devastating nature of the disease that often results in early mortality further constrain market growth. Despite these challenges, opportunities exist in emerging markets with improving healthcare systems, increased collaboration between academic institutions and pharmaceutical companies, and growing patient advocacy efforts. The development of biomarkers for disease monitoring, expansion of newborn screening programs, and potential combination therapy approaches represent additional market opportunities that could drive future growth and improve patient outcomes.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Tay-Sachs disease market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include IntraBio Inc, Recursion Pharmaceuticals, Inc., Forge Biologics, Taysha Gene Therapies, JCR Pharmaceuticals Co., Ltd., Sanofi, and Sio Gene Therapies.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global Tay-Sachs disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Tay-Sachs disease market
Market Segmentation
- Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
- Infantile Tay-Sachs Disease
- Juvenile Tay-Sachs Disease
- Late-Onset Tay-Sachs Disease
- Treatment Type Insights (Revenue, USD Bn, 2021 - 2033)
- Gene Therapy
- N-Acetyl-L-Leucine
- Venglustat (Substrate Reduction Therapy)
- Other Pipeline Drugs/Therapy
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Others
- End User Insights (Revenue, USD Bn, 2021 - 2033)
- Hospitals and Specialty Neurology Clinics
- Diagnostic Laboratories and Genetic Centers
- Research and Academic Institutes
- Homecare Settings
- Patient Support Organizations
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- IntraBio Inc
- Recursion Pharmaceuticals, Inc.
- Forge Biologics
- Taysha Gene Therapies
- JCR Pharmaceuticals Co., Ltd.
- Sanofi
- Sio Gene Therapies
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Tay-Sachs Disease Market, By Disease Type
- Global Tay-Sachs Disease Market, By Treatment Type
- Global Tay-Sachs Disease Market, By Route of Administration
- Global Tay-Sachs Disease Market, By End User
- Global Tay-Sachs Disease Market, By Distribution Channel
- Global Tay-Sachs Disease Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Tay-Sachs Disease Market, By Disease Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Infantile Tay-Sachs Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Juvenile Tay-Sachs Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Late-Onset Tay-Sachs Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Tay-Sachs Disease Market, By Treatment Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- N-Acetyl-L-Leucine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Venglustat (substrate Reduction Therapy)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Other Pipeline Drugs/Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Tay-Sachs Disease Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Tay-Sachs Disease Market, By End User, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals and Specialty Neurology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Diagnostic Laboratories and Genetic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Research and Academic Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Patient Support Organizations
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Tay-Sachs Disease Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Tay-Sachs Disease Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn) Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- IntraBio Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Recursion Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Forge Biologics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Taysha Gene Therapies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- JCR Pharmaceuticals Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sio Gene Therapies
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About Us
